Needham & Company LLC upgraded shares of Clearside Biomedical (NASDAQ:CLSD – Get Rating) from a hold rating to a buy rating in a report published on Thursday, The Fly reports. They currently have $5.00 price target on the stock.
A number of other equities research analysts have also weighed in on CLSD. HC Wainwright boosted their price objective on Clearside Biomedical from $5.00 to $6.00 and gave the stock a buy rating in a research report on Thursday. Stifel Nicolaus upgraded Clearside Biomedical from a hold rating to a buy rating and set a $8.00 price objective on the stock in a research report on Wednesday, November 9th. Finally, StockNews.com began coverage on Clearside Biomedical in a research report on Friday, November 4th. They set a hold rating on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $7.60.
Clearside Biomedical Stock Up 0.8 %
Shares of CLSD stock opened at $1.33 on Thursday. The firm has a market capitalization of $80.05 million, a P/E ratio of -16.63 and a beta of 1.84. Clearside Biomedical has a twelve month low of $1.00 and a twelve month high of $4.98. The stock’s fifty day simple moving average is $1.24 and its 200 day simple moving average is $1.41.
Hedge Funds Weigh In On Clearside Biomedical
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
- Get a free copy of the StockNews.com research report on Clearside Biomedical (CLSD)
- Alphabet Stock Offers a Rare Buying Opportunity
- Walt Disney Stock is Set to Reset Expectations
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.